ERBB2 and breast cancer: Strikingly, treatment of RSL3-resistant luminal BC cell lines with RSL3 resulted in a marked increase in targets associated with the BIOCARTA_HER2_PATHWAY gene-set (https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/BIOCARTA_HER2_PATHWAY.html?keywords=HER2).